Page 14 - Read Online

Page 8 of 9 Tyerman et al. J Cancer Metastasis Treat 2022;8:29 https://dx.doi.org/10.20517/2394-4722.2022.20

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception and design of the study and performed article analysis and
interpretation: Tyerman Z, Ambler E, Chawla A
Provided administrative, technical, and editorial support: Schlick CJR, Nwajei F

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Centers for Disease Control and Prevention, An update on cancer deaths in the United States, 2021. Available from:
https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm [Last accessed on 20 July 2022].
2. American Cancer Society, Cancer facts & figures 2021. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-
cancer-facts-figures/cancer-facts-figures-2021.html [Last accessed on 20 July 2022].
3. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis,
epidemiology, treatment and outcomes. World J Gastroenterol 2018;24:4846-61. DOI PubMed PMC
4. Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for recurrent pancreatic cancer: is it effective?
Cancers (Basel) 2019;11:991. DOI PubMed PMC
5. Komo T, Murakami Y, Kondo N, et al. Prognostic impact of para-aortic lymph node micrometastasis in pancreatic ductal
adenocarcinoma. Ann Surg Oncol 2016;23:2019-27. DOI PubMed
6. Niedergethmann M, Rexin M, Knob S, et al. [Detection of micrometastases after curative resection for ductal adenocarcinoma of the
pancreas]. Zentralbl Chir 2001;126:917-21. DOI PubMed
7. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can
predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-902. DOI PubMed
PMC
8. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 2003;58:667-72. PubMed
9. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for
pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6. DOI PubMed
10. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer-a comprehensive review. Indian J Surg
Oncol 2011;2:88-100. DOI PubMed PMC
11. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic
adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105-19. DOI PubMed PMC
12. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group On Tumor Markers (EGTM) status
report. Ann Oncol 2010;21:441-7. DOI PubMed
13. Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil 1948;142:241-3. PubMed
14. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res
1977;37:646-50. PubMed
15. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput
Struct Biotechnol J 2018;16:370-8. DOI PubMed PMC